Adoptive immunotherapy with recombinant human IL-2 (rHuIL-2) after autologous stem cell transplantation (ASCT) for high-risk neuroblastoma (HR-NB).

被引：0
|
作者：
Pession, A
Prete, A
Locatelli, F
Alvisi, P
Garaventa, A
Messina, C
Pierinelli, S
Bonetti, F
Cordero, L
Favre, C
Arrighini, A
Rondelli, R
DeBernandi, B
Paolucci, G
机构：
[1] DEPT PEDIAT,PAVIA,ITALY
[2] DEPT PEDIAT,TURIN,ITALY
[3] DEPT PEDIAT,PADUA,ITALY
[4] DEPT PEDIAT,PISA,ITALY
[5] DEPT PEDIAT,BRESCIA,ITALY
[6] DEPT PEDIAT,GENOA,ITALY
来源：
EXPERIMENTAL HEMATOLOGY | 1996年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：374 / 374
页数：1
相关论文
共 50 条
  • [41] Treatment with interleukin-2 (IL-2) and interferon (IFNalpha 2b) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse
    P Vivancos
    A Grañena Jr
    J Sarrá
    A Grañena
    Bone Marrow Transplantation, 1999, 23 : 169 - 172
  • [42] SUCCESS OF CHIMERIC ANTI-GD2 ANTIBODY+GM-CSF+IL2 IMMUNOTHERAPY IN HIGH-RISK NEUROBLASTOMA (NB) IN FIRST RESPONSE: A CRITICAL APPRAISAL
    London, Wendy B.
    Sondel, Paul
    Gilman, Andrew L.
    Ozkaynak, Fevzi
    Kreissman, Susan
    Buxton, Allen
    Chen, Helen
    Matthay, Katherine K.
    Cohn, Susan L.
    Maris, John M.
    Yu, Alice L.
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 708 - 708
  • [43] Assessment of the Wilms' Tumor Gene (WT1) Expression in High-Risk Neuroblastoma (NB) Patients WHO Underwent Autologous Hematopoietic Stem Cell Transplantation (HSCT)
    Khan, Sana
    Olszewski, Marie
    Kletzel, Morris
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S114 - S114
  • [44] Immunotherapy with IL-2 expressing allogeneic tumor cells after primary therapy for high-risk neuroblastoma: Clinical outcomes and generation of both cellular and humoral immune responses.
    Haight, AE
    Davidoff, AM
    Ng, CYC
    Vanin, EF
    Bowman, LC
    BLOOD, 2000, 96 (11) : 801A - 801A
  • [45] High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma – a phase II study
    HC Toh
    SL McAfee
    R Sackstein
    P Multani
    BF Cox
    R Garcia-Carbonero
    C Colby
    TR Spitzer
    Bone Marrow Transplantation, 2000, 25 : 19 - 24
  • [46] IMMUNOTHERAPY WITH RITUXIMAB (RITUXAN)/INTERLEUKIN 2 (IL-2) FOLLOWING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (ASCT) AS TREATMENT FOR CD20 POSITIVE NON-HODGKIN'S LYMPHOMA
    Holmberg, L. A.
    Maloney, D. G.
    Bensinger, W., I
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 39 - 39
  • [47] THE FUNCTION OF HYPOTALAMO-PITUITARY-GONADAL AXIS AFTER CHILDHOOD HIGH-RISK NEUROBLASTOMA TREATED WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION
    Utriainen, Pauliina
    Vatanen, Anu
    Makitie, Outi
    Jahnukainen, Kirsi
    HORMONE RESEARCH IN PAEDIATRICS, 2017, 88 : 546 - 546
  • [48] High-dose cyclophosphamide plus carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study
    Toh, HC
    McAfee, SL
    Sackstein, R
    Multani, P
    Cox, BF
    Garcia-Carbonero, R
    Colby, C
    Spitzer, TR
    BONE MARROW TRANSPLANTATION, 2000, 25 (01) : 19 - 24
  • [49] Early and prolonged D1-86 administration of low dose interleukin 2 (IL2) after autologous stem cell transplantation (ASCT) for haematologic malignancies.
    Stoppa, AM
    Vey, N
    Viret, F
    Chabbert, I
    Faucher, C
    Chabannon, C
    Bouabdallah, R
    Coso, D
    Gastaut, JA
    Maraninchi, D
    Blaise, D
    BLOOD, 1998, 92 (10) : 295A - 295A
  • [50] INTENSIVE IMMUNOTHERAPY WITH RECOMBINANT IL2 AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION IS ASSOCIATED WITH A HIGH-INCIDENCE OF BACTERIAL-INFECTIONS
    BLAISE, D
    STOPPA, AM
    VIENS, P
    SAINTY, D
    FOSSAT, C
    MIQUEL, M
    OLIVE, D
    BOUABDALLAH, R
    GABERT, J
    BAUME, D
    MARANINCHI, D
    BONE MARROW TRANSPLANTATION, 1992, 10 (02) : 193 - 194
12345